Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Emmanuel S. Antonarakis

doi:10.1038/aja.2012.45

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Emmanuel S. Antonarakis

School of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

Original language	English (US)
Pages (from-to)	520-521
Number of pages	2
Journal	Asian Journal of Andrology
Volume	14
Issue number	4
DOIs	https://doi.org/10.1038/aja.2012.45
State	Published - Jul 2012

ASJC Scopus subject areas

Urology

Access to Document

10.1038/aja.2012.45

Cite this

@article{7a77e5bef1f049eda6f92ca51bd53115,

title = "Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer",

abstract = "Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.",

author = "Antonarakis, {Emmanuel S.}",

year = "2012",

month = jul,

doi = "10.1038/aja.2012.45",

language = "English (US)",

volume = "14",

pages = "520--521",

journal = "Asian Journal of Andrology",

issn = "1008-682X",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

AU - Antonarakis, Emmanuel S.

PY - 2012/7

Y1 - 2012/7

N2 - Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

AB - Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863695808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863695808&partnerID=8YFLogxK

U2 - 10.1038/aja.2012.45

DO - 10.1038/aja.2012.45

M3 - Article

C2 - 22580638

AN - SCOPUS:84863695808

SN - 1008-682X

VL - 14

SP - 520

EP - 521

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

IS - 4

ER -

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this